Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 HKD | +0.60% | +5.62% | -28.09% |
Apr. 11 | Lifetech Scientific Buys Shares For Employee Incentive Scheme | MT |
Apr. 04 | Lifetech Scientific Unit Invests 340 Million Yuan in Structured Deposits | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.09% | 994M | - | ||
+8.07% | 219B | B | ||
+6.59% | 183B | B- | ||
+11.26% | 133B | B- | ||
+26.57% | 108B | A- | ||
+1.25% | 63.06B | A- | ||
+13.35% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.93% | 40.37B | A | ||
+11.54% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1302 Stock
- Ratings LifeTech Scientific Corporation